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276Stevens-Johnson Syndrome and Corneal Ectasia:
Management and a Case for AssociationHAJIRAH N. SAEED, SAHAR KOHANIM, HONG-GAM LE, JAMES CHODOSH, AND DEBORAH S. JACOBS PURPOSE: To report the occurrence of corneal ectasia
(ECT) in patients with history of Stevens-Johnson syn-
drome (SJS), and to make the case for an association
between these 2 diagnoses. We also report the impact of
prosthetic replacement of the ocular surface ecosystem
(PROSE) treatment on visual acuity (VA) in these
patients.
 DESIGN: Retrospective cohort study.
 METHODS: A manufacturing database of PROSE
patients from 2002 to 2014 at Boston Foundation for
Sight (BFS), a single-center clinical practice, was
reviewed to identify patients with diagnoses of both SJS
and ECT.
 RESULTS: Nine patients were identified with diagnoses
of both SJS and ECT. In each case, review of the medical
record revealed that diagnosis of SJS preceded that of
ECT. The prevalence of ECT in this population exceeded
that in the general population (P< .0001). Videokera-
tography was available for 13 eyes in 7 patients; using
Krumeich’s classification of keratoconus, 3 eyes were
found to be at stage 1, 3 at stage 2, 1 at stage 3, and 6
at stage 4. Sixteen of 18 eyes underwent PROSE treat-
ment. Of these 16 eyes, initial median VA was 20/200
(range, count fingers to 20/20; logMAR 1.0). Median
VA after PROSE customization was 20/30 (range, 20/
60–20/15; logMAR 0.1761, P< .0025).
 CONCLUSIONS: ECT occurs at a higher-than-expected
rate in patients with a history of SJS. PROSE treatment
improves VA in these patients. The basis of the associa-
tion between SJS and ECT is considered, as well as the
role of plausible contributory factors such as corneal
microtrauma and matrix metalloproteinases. (Am J
Ophthalmol 2016;169:276–281.  2016 The
Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).)upplemental Material available at AJO.com.
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TEVENS-JOHNSON SYNDROME (SJS) AND ITS MORE
severe form, toxic epidermal necrolysis (TEN), are
on a spectrum of immune-mediated, mucocutaneous
diseases triggered by medications and, less commonly, in-
fections.1,2 SJS/TEN is typified by an acute febrile illness
associated with prodromal target lesions, followed by skin
detachment and involvement of at least 2 mucous
membrane sites.3 Ocular surface involvement occurs in
50%-78% of SJS/TEN cases and can result in significant
long-term ocular sequelae, with 35% of survivors of SJS/
TEN experiencing permanent vision loss.4,5
Long-term medical and surgical management of patients
with severe ocular surface disease, as can occur after SJS/
TEN, is complex. One form of nonsurgical management
is the use of therapeutic contact lenses.6–9 Clinicians may
hesitate to consider therapeutic contact lenses in SJS/
TEN patients because of assumptions that cicatricial
conjunctival changes may be a barrier to achieving
satisfactory fit. Additionally, these patients might be
excluded as candidates because of ocular comorbidities
such as aqueous tear deficiency and limbal stem cell
deficiency that together would put patients in a high-risk
category for epithelial breakdown and superinfection.
Prosthetic replacement of the ocular surface ecosystem
(PROSE) is a treatment approach developed by Boston
Foundation for Sight (BFS), Needham, Massachusetts,
that uses a custom-designed and fitted, FDA-approved,
rigid gas-permeable scleral lens prosthetic device to support
ocular surface functions. The devices used in PROSE treat-
ment vault the cornea and limbus and rest on sclera. They
are filled with sterile saline at the time of application, worn
on a daily-wear basis, and removed for sleep (Figure 1).10,11
PROSE treatment is also used in the management of
corneal ectasia (ECT),11,12 a degenerative disorder that
manifests as progressive corneal thinning and steepening.
The resultant irregular astigmatism, myopia, and irregular
corneal surface can lead to impaired vision and can
require surgical intervention.13 The most common of the
corneal ectasias is keratoconus (KC). KC is also the most
common condition requiring scleral lens wear.12 Scleral
lenses have been shown to improve visual acuity and com-
fort in patients with KC.14 However, when scleral lenses
and other treatment options fail, PROSE treatment has
been shown to significantly improve vision and visual func-
tion,8,11,15 which may delay and perhaps eliminate the
need for surgical intervention with its inherent risks and
unpredictability.0002-9394
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FIGURE 1. Prosthetic replacement of the ocular surface
ecosystem (PROSE) device filled with sterile saline prior to
insertion.
TABLE 1. Clinical Classification of Patients With Stevens-
Johnson Syndrome and Corneal Ectasia by Stage Using the
Krumeich Classification of Keratoconusa
Stageb Characteristics
Number of Eyes
at Each Stage
1 Eccentric steepening
Induced myopia and/or astigmatism of
<_5.00 D
K-reading <_48.00 D
Vogt lines, typical topography
3
2 Induced myopia and/or astigmatism of
5.00 to <_8.00 D
K-reading <_53.00 D
Pachymetry >_400 mm
3
3 Induced myopia and/or astigmatism of
8.00 to <_10.00 D
K-reading >53.00 D
Pachymetry 200–400 mm
1
4 Refraction not measurable
K-reading >55.00 D
Central scars
Pachymetry <_200 mm
6
D ¼ diopters.
Pachymetry is measured at the thinnest site of the cornea.
aAdapted from Krumeich et al.16
bStage is determined if 1 of the characteristics applies.In the course of a medical records review of patients with
SJS/TEN, we noticed several patients who also had a diag-
nosis of ECT. This coincidence was striking, given the rar-
ity of each condition. We present a review of 9 such cases
here. Though the literature addresses corneal pathophysi-
ology in SJS/TEN and ectatic disorders individually, to
our knowledge, there are no reports of the prevalence,
pathogenesis, and management of these entities as associ-
ated disorders.METHODS
THIS STUDY WAS CONDUCTED ACCORDING TO THE DECLA-
ration of Helsinki, was compliant with the Health Insur-
ance Portability and Accountability Act (HIPAA), and
was determined to be exempt from review by the New En-
gland Institutional Review Board. A manufacturing data-
base of PROSE patients from January 1, 2002 to
December 31, 2014 at BFS was searched to identify patients
with diagnoses of both SJS/TEN and ECT. Referral to BFS
occurred for management of poor or worsening visual func-
tion. All cases of ectasia were first diagnosed by the refer-
ring ophthalmologist and independently confirmed atVOL. 169 STEVENS-JOHNSON SYNDBFS at the time of consultation. For this study, the diag-
nosis of ECT was confirmed by reviewing clinical examina-
tion notes and videokeratography. The Krumeich staged
clinical classification of KC was used to stage the level of
disease.16 Though the accuracy of videokeratographic
data in SJS/TEN is unknown, generation of central 3-mm
simulated keratometry (sim K) values was designated as a
reliable measurement of keratometry values for Krumeich
classification. Other relevant data were extracted from
the medical records, with visual acuity recorded in Snellen
format and then converted to logarithm of the minimum
angle of resolution (logMAR) for analysis. Statistical anal-
ysis was performed using the InStat statistical package by
GraphPad Software, Inc (La Jolla, California, USA) with
the level of statistical significance set at .05.RESULTS
TWO HUNDRED FIFTY PATIENTS WITH A DIAGNOSIS OF SJS/
TEN were identified in the BFS database of patients for
whom prosthetic devices were manufactured between
2002 and 2014. Seventeen eyes in 9 of these patients had
been coded with a secondary diagnosis of ECT. Review of
referral letters, notes, and records revealed that in each of
these 9 cases, the diagnosis of ECT was made after acute
SJS/TEN, with a range of 1–33 years.277ROME AND ECTASIA
TABLE 2. Patient Demographics and Clinical Data for Patients With Stevens Johnson Syndrome and Corneal Ectasia
Patient Characteristics
Patient
1 2 3 4 5 6 7 8 9
Age at diagnosis of SJS 30 26 5 7 10 23 4 2 7
Age at diagnosis of ectasia 36 34 14 8 22 29 13 35 12
Age at PROSE treatment 40 34 44 41 29 29 23 37 28
Sex F F F F F M M M F
Pre-PROSE BCVA OD NF (20/25) 20/400 CF 20/400 20/100 20/300 20/30 20/20 NF (20/20)
Post-PROSE BCVA OD NF 20/30 20/50 20/30 20/40 20/20 20/20 20/15 NF
Steepest sim K OD 45.42 Not available Not available 59.0 80.5 53.5 43.6 43.8a 47.73
Pre-PROSE BCVA OS 20/400 20/400 CF 20/50 20/50 20/200 20/400 20/40 20/60
Post-PROSE BCVA OS 20/40 20/30 20/40 20/20 20/20 20/60 20/30 20/20 20/40
Steepest sim K OS 59.00 Not available Not available 52.1 59.4 63.4 68.6 48.4a Inadequate image
for 3-mm sim K
Follow-up duration (mo) 4 58 0.5 16 120 12 0.5 20 120
Krumeich stage of cornea
(OD//OS)
1//4 NA NA 4//2 4//4 3//4 1//4 1//2 2//NA
BCVA¼ best-corrected visual acuity; CF¼ count fingers; NF¼ not fitted for PROSE; PROSE¼ prosthetic replacement of the ocular surface
ecosystem; Sim K ¼ simulated keratometry; SJS ¼ Stevens-Johnson syndrome.
aPellucid marginal degeneration topography pattern, I-S value of >1.5, and thinning by Scheimpflug imaging.Sixteen of 18 eyes had clinical and slit-lamp findings of
an ectatic disorder, with videokeratography on record for
14 eyes of 7 patients. Thirteen of these eyes had sufficient
videokeratographic data to generate 3-mm sim K values,
which were used for keratoconus staging using the
Krumeich classification16 (Table 1). Table 2 presents de-
mographic and clinical data on these patients. In 1 eye of
1 patient (Patient 4) there were rigid gas-permeable
corneal contact lens data available from which corneal cur-
vature was derived as 48.00 diopters (D). Sim K values from
videokeratography reveal keratometries of 43.2 D3 52.1 D
with a mean of 47.65 D, suggesting that sim K values are
valid representations of steepness in these patients. For 2
eyes of 1 other patient (Patient 8) there are Scheimpflug
imaging data supporting diagnosis of ectasia.
Figure 2 illustrates the slit-lamp and videokeratography
findings of Patient 6.
Based on use of a commonly cited KC prevalence rate of
54.5 per 100 000 population,17 the prevalence of ECT
among SJS/TEN patients in the BFS manufacturing data-
base as compared with that of the general population was
statistically significant (P < .0001, Fisher exact test). It
was not possible to determine progression, if any, of ECT
in the SJS/TEN patients compared with that in the general
population owing to limited data points.
The median visual acuity at the initial visit, in habitual
correction, was 20/200 (range, count fingers to 20/20;
logMAR 1.0), whereas the median visual acuity at comple-
tion of customization was 20/30 (range, 20/60–20/15;
logMAR 0.1761, P < .0025, McNemar test). All eyes
that underwent PROSE treatment attained best-corrected
visual acuity of >_20/60 (P¼ .002), with most eyes attaining278 AMERICAN JOURNAL OF20/30 vision or better (P ¼ .008). Vision with PROSE
treatment was maintained in all patients, with a median
duration of follow-up of 14 months (range, 0.5–
120 months), consistent with findings among SJS/TEN pa-
tients in general with PROSE treatment.18
The interval between diagnosis of ECT and initial
consultation for PROSE treatment ranged from 0 to 33
years, with a mean of 9 years, and did not correlate to final
BCVA (r ¼ 0.1432; P ¼ .6253, Pearson correlation) or to
the severity of ECT at the time of initial consultation
(r ¼ 0.0132, P ¼ .9693, Pearson correlation).
The Oxford scheme was used to assess dry eye state at the
time of consultation in 8 of 18 eyes. There was a tendency
for higher initial Oxford scheme scores to correlate with
higher KC stage, but this was not statistically significant
(r ¼ 0.6054; P ¼ .1491, Pearson correlation). Post-
PROSE Oxford scheme scores are not available.DISCUSSION
THE ASSOCIATION OF ECT WITH SJS/TEN AMONG PATIENTS
in the BFS manufacturing database is highly significant.
Review of their medical records revealed that for each of
the 9 patients described, the diagnosis of ECT was made
at some time after acute SJS/TEN, suggesting that ECT
may be a further ocular complication of SJS/TEN. This
sequential association warrants further research into path-
ophysiologic mechanisms. Patients with acute SJS/TEN
have severe inflammation and ulceration of the tarsal con-
junctiva and eyelid margins, leading to tarsal scarring,SEPTEMBER 2016OPHTHALMOLOGY
FIGURE 2. Slit-lamp and keratography findings in a patient with Stevens-Johnson syndrome and corneal ectasia (Patient 6). (Top
left) Topography of the right eye demonstrating a paracentral nasal cone with a steep K of 53.55 diopters. (Top right) Topography of
the left eye demonstrating a central cone with a steep K of 63.40 diopters. (Middle left) Keratinization of the bulbar conjunctival sur-
face of the right eye. (Middle right) Keratinization of the tarsal conjunctiva of the left eye. (Bottom left) Right eye in a PROSE device.
(Bottom right) Left eye in a PROSE device.eyelid margin keratinization, and lipid tear deficiency.
These changes can lead to corneal complications from
blink-related microtrauma.19 However, there are no reports
in the literature directly addressing a relationship between
microtrauma in SJS/TEN and ECT. Data from Dogru and
associates suggest that tear function disturbance and ocular
surface disease contributes to the progression of KC.20 They
propose that abnormal eyelid–cornea interactions may
contribute to ECT via altered tear film stability, loss of
goblet cells, and subsequent squamous metaplasia, possibly
frommatrix metalloproteinase (MMP) expression by meta-
plastic epithelial cells. All of these ocular changes haveVOL. 169 STEVENS-JOHNSON SYNDbeen demonstrated in SJS/TEN eyes, although their signif-
icance in the development of ECT has not been
researched.1,19 Future studies might look for correlation
between eyelid pathology and presence or extent of ECT.
Other studies postulate that the defect in KC may lie in
extracellular matrix degradation in the cornea.20 Though
there are varying reports in the literature and no consensus,
the potential role for degradative enzymes, including
MMPs, tissue inhibitor of metalloproteinases-1(TIMP-1),
and cytokines, in the pathogenesis of KC have been re-
ported. Elevated levels of MMPs, particularly collagenases
and gelatinases, have been demonstrated in KC eyes, along279ROME AND ECTASIA
with decreased levels of TIMP-1. Particular MMPs demon-
strated to be elevated in KC eyes include MMP-1, MMP-3,
MMP-7, MMP-9, and MMP-13. MMP-2 has also been
implicated by virtue of elevated levels of membrane-type
MMP in KC eyes, which can in turn activate MMP-
2.13,20–27 Some of these MMPs have also been
demonstrated to be elevated in the tears of SJS/TEN
patients. This elevation combined with a decrease in
MMP regulation may predispose SJS/TEN patients to
corneal remodeling. In 1 study of tears of SJS/TEN
patients, MMP-8, MMP-9, and myeloperoxidase were all
found to be significantly elevated, with lesser increases in
MMP-2 and MMP-3.28 Future studies on MMPs and other
effectors in the subset of SJS/TEN patients with coexisting
ECT are indicated to further elucidate the putative rela-
tionship between the 2 diseases.
Elevated MMPs have been found to be elevated in gen-
eral ocular surface disease, including dry eye,29–31 and may
be a contributory factor in the mechanism of ECT in SJS/
TEN patients. A case series by de Paiva and associates
suggested that chronic desiccation may produce inferior
corneal steepening and that this can be reversed with
lubrication.32 A pilot study by Carracedo and associates
demonstrated that KC patients have reduced goblet cell
density and tear volumes, have higher ocular surface dis-
ease index scores, and suffer greater symptoms of dry eye
than control subjects.33 Whether a dry eye state precedes
the development of KC or vice versa is unclear.
We note that that each one of our patients with SJS and
subsequent ECT developed SJS in the first, second, or third
decade of life. Keratoconus tends to progress in the second
and third decades. Further analysis and a larger sample
would be required to determine if age is protective against
subsequent ECT in SJS.
Though it was not statistically significant, we did find a
correlation between higher Oxford scheme score for dry
eye and higher ectatic stage, using the Krumeich classifica-
tion. PROSE treatment significantly improved BCVA in
all patients. It is unknown whether PROSE treatment can
reverse topographic changes. Longitudinal studies would
be needed to study the effect of PROSEonECT inSJS/TEN.280 AMERICAN JOURNAL OFManagement of ECT typically is stepwise, starting with
glasses, rigid gas-permeable contact lenses, collagen cross-
linking, and/or intracorneal ring segments, and then as
required, to lamellar or full-thickness keratoplasty, each
with high rates of success.34,35 The coexistence of SJS/
TEN with ECT complicates management, as ocular
surface disease interferes with successful wear of corneal
rigid gas-permeable lenses and healing after any corneal
surgery. The development of ECT during the chronic phase
of SJS/TEN represents a particularly difficult therapeutic
challenge.
PROSE treatment has been shown to be a cost-effective
and cost-beneficial means of improving visual acuity, visual
function, ocular surface comfort, healing, and quality of life
in patients with irregular corneas and with ocular surface
disease,8,36 including the specific subsets of patients with
SJS/TEN18,37,38 and KC.11,12 PROSE treatment appears
especially well suited to patients in whom ECT and SJS/
TEN are associated.
Limitations of our study include its retrospective
design, low sample size, and lack of a control group.
Our use of steepest sim K values as support for diagnosis
of ectasia can be challenged, as patients with keratocon-
junctivitis sicca may have reversible topographic corneal
steepening. Pachymetry mapping, not available when
most of these patients were first seen in consultation
and not generally used for PROSE treatment, would be
useful for better characterization of the ECT in these
SJS patients. Additional data points over time would
be useful to assess progression of ECT. Because patients
with coexisting SJS/TEN and ECT may be more likely
to be referred for PROSE treatment, the apparent associ-
ation of these 2 disorders may represent a bias of ascer-
tainment.
This first report of the association of ECT with SJS/TEN
patients should be of interest to researchers studying either
condition. Furthermore, the rehabilitation of SJS/TEN and
ECT as coexisting disorders with PROSE treatment should
be of interest to clinicians. Further studies are warranted to
characterize the apparent association of ECT with SJS/
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